
TY  - JOUR
TI  - Basic Science Podium/Poster
JO  - Neurourology and Urodynamics
JA  - Neurourology and Urodynamics
VL  - 38
IS  - S1
SN  - 0733-2467
UR  - https://doi.org/10.1002/nau.23949
DO  - doi:10.1002/nau.23949
SP  - S6
EP  - S255
PY  - 2019
ER  - 

TY  - JOUR
TI  - Proceedings 22nd Symposium ESVN-ECVN Bologna 24th–26th September 2009
JO  - Journal of Veterinary Internal Medicine
VL  - 24
IS  - 1
SN  - 0891-6640
UR  - https://doi.org/10.1111/j.1939-1676.2009.00446.x
DO  - doi:10.1111/j.1939-1676.2009.00446.x
SP  - 235
EP  - 258
PY  - 2010
ER  - 

TY  - JOUR
TI  - Abstracts 662 to 889
JO  - Hepatology
JA  - Hepatology
VL  - 46
IS  - S1
SN  - 0270-9139
UR  - https://doi.org/10.1002/hep.22019
DO  - doi:10.1002/hep.22019
SP  - 532A
EP  - 631A
PY  - 2007
ER  - 

TY  - JOUR
TI  - Research Communications of the 24th ECVIM-CA Congress
JO  - Journal of Veterinary Internal Medicine
JA  - J Vet Intern Med
VL  - 29
IS  - 1
SN  - 0891-6640
UR  - https://doi.org/10.1111/jvim.12491
DO  - doi:10.1111/jvim.12491
SP  - 423
EP  - 483
PY  - 2015
ER  - 

TY  - JOUR
TI  - Poster Sessions
JO  - The FEBS Journal
JA  - FEBS J
VL  - 281
IS  - s1
SN  - 1742-464X
UR  - https://doi.org/10.1111/febs.12919
DO  - doi:10.1111/febs.12919
SP  - 65
EP  - 784
PY  - 2014
ER  - 

TY  - JOUR
TI  - EACS 2019 – Abstract Book
JO  - HIV Medicine
JA  - HIV Med
VL  - 20
IS  - S9
SN  - 1464-2662
UR  - https://doi.org/10.1111/hiv.12814
DO  - doi:10.1111/hiv.12814
SP  - 3
EP  - 316
PY  - 2019
ER  - 

TY  - JOUR
TI  - Poster
JO  - Journal of Hepato-Biliary-Pancreatic Sciences
JA  - J Hepatobiliary Pancreat Sci
VL  - 24
IS  - S1
SN  - 1868-6974
UR  - https://doi.org/10.1002/jhbp.480
DO  - doi:10.1002/jhbp.480
SP  - A235
EP  - A394
PY  - 2017
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Journal of Medical Primatology
JA  - J Med Primatol
VL  - 42
IS  - 5
SN  - 0047-2565
UR  - https://doi.org/10.1111/jmp.12066
DO  - doi:10.1111/jmp.12066
SP  - 254
EP  - 285
PY  - 2013
ER  - 

TY  - JOUR
TI  - 46th Congress of the International Society of Paediatric Oncology (SIOP) 2014
JO  - Pediatric Blood & Cancer
JA  - Pediatr Blood Cancer
VL  - 61
IS  - S2
SN  - 1545-5009
UR  - https://doi.org/10.1002/pbc.25314
DO  - doi:10.1002/pbc.25314
SP  - S105
EP  - S433
PY  - 2014
ER  - 

TY  - JOUR
TI  - Oral Abstract Session OAS
JO  - Allergy
JA  - Allergy
VL  - 71
IS  - S102
SN  - 0105-4538
UR  - https://doi.org/10.1111/all.12970
DO  - doi:10.1111/all.12970
SP  - 3
EP  - 94
PY  - 2016
ER  - 

TY  - JOUR
TI  - Oral Abstract Sessions
JO  - Allergy
VL  - 66
IS  - s94
SN  - 0105-4538
UR  - https://doi.org/10.1111/j.1398-9995.2011.02604.x
DO  - doi:10.1111/j.1398-9995.2011.02604.x
SP  - 1
EP  - 104
PY  - 2011
ER  - 

TY  - JOUR
TI  - 2014 ACVIM Forum Research Abstracts Program
JO  - Journal of Veterinary Internal Medicine
JA  - J Vet Intern Med
VL  - 28
IS  - 3
SN  - 0891-6640
UR  - https://doi.org/10.1111/jvim.12361
DO  - doi:10.1111/jvim.12361
SP  - 976
EP  - 1134
PY  - 2014
ER  - 

TY  - JOUR
TI  - American Society of Pediatric Hematology/Oncology 23rd Annual Meeting: Abstracts
JO  - Pediatric Blood & Cancer
JA  - Pediatr. Blood Cancer
VL  - 54
IS  - 6
SN  - 1545-5009
UR  - https://doi.org/10.1002/pbc.22516
DO  - doi:10.1002/pbc.22516
SP  - 787
EP  - 864
PY  - 2010
ER  - 

TY  - JOUR
TI  - Australasian College of Dermatologists Abstracts Presented at the 49th Annual Scientific Meeting 14–17 May 2016 Perth, Western Australia
JO  - Australasian Journal of Dermatology
JA  - Australas J Dermatol
VL  - 57
IS  - S1
SN  - 0004-8380
UR  - https://doi.org/10.1111/ajd.12480
DO  - doi:10.1111/ajd.12480
SP  - 3
EP  - 85
PY  - 2016
ER  - 

TY  - JOUR
TI  - ASBMR 23nd annual meeting
JO  - Journal of Bone and Mineral Research
JA  - J Bone Miner Res
VL  - 16
IS  - S1
SN  - 0884-0431
UR  - https://doi.org/10.1002/jbmr200116s1s1
DO  - doi:10.1002/jbmr200116s1s1
SP  - S1
EP  - S390
PY  - 2001
ER  - 

TY  - JOUR
TI  - ILTS
JO  - Liver Transplantation
JA  - Liver Transpl
VL  - 12
IS  - 5
SN  - 1527-6465
UR  - https://doi.org/10.1002/lt.20832
DO  - doi:10.1002/lt.20832
SP  - C1
EP  - C142
PY  - 2006
ER  - 

TY  - JOUR
TI  - GLIA Porto 2019: Abstracts Oral Presentations, Posters, Indexes
JO  - Glia
JA  - Glia
VL  - 67
IS  - S1
SN  - 0894-1491
UR  - https://doi.org/10.1002/glia.23675
DO  - doi:10.1002/glia.23675
SP  - E125
EP  - E766
PY  - 2019
ER  - 

TY  - JOUR
TI  - Coagulation - laboratory
JO  - British Journal of Haematology
VL  - 86
IS  - s1
SN  - 0007-1048
UR  - https://doi.org/10.1111/j.1365-2141.1994.tb04861.x
DO  - doi:10.1111/j.1365-2141.1994.tb04861.x
SP  - 2
EP  - 92
PY  - 1994
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - European Journal of Heart Failure
JA  - Eur J Heart Fail
VL  - 19
IS  - S1
SN  - 1388-9842
UR  - https://doi.org/10.1002/ejhf.833
DO  - doi:10.1002/ejhf.833
SP  - 5
EP  - 601
PY  - 2017
ER  - 

TY  - JOUR
AU  - Muwakkit, Samar
AU  - Al-Aridi, Carol
AU  - Samra, Ahmad
AU  - Saab, Raya
AU  - Mahfouz, Rami A.
AU  - Farra, Chantal
AU  - Jeha, Sima
AU  - Abboud, Miguel R.
TI  - Implementation of an intensive risk-stratified treatment protocol for children and adolescents with acute lymphoblastic leukemia in Lebanon
JO  - American Journal of Hematology
JA  - Am. J. Hematol.
VL  - 87
IS  - 7
SN  - 0361-8609
UR  - https://doi.org/10.1002/ajh.23222
DO  - doi:10.1002/ajh.23222
SP  - 678
EP  - 683
PY  - 2012
AB  - Abstract With modern risk-adapted therapy, over 80% of children with acute lymphoblastic leukemia (ALL) in high-income countries (HICs) are cured. In countries with limited resources, however, therapy results for pediatric ALL are still not encouraging. We describe our experience in treating children with ALL using a risk-adapted protocol at a tertiary referral center in Lebanon. From May 2002 to August 2009, 111 consecutive patients 1?21 years of age with newly diagnosed ALL received the CCCL ALL protocol which was based on the St. Jude Children's Research Hospital Total XV Study. The median age at diagnosis was 5 years 5 months. The male to female ratio was 1.5. Forty-six patients received the intermediate-/high-risk arm and 65 received the low-risk arm. Only one patient (0.9%) died during induction therapy. Relapse occurred in 8 (7.2%) patients. Eight (7.2%) patients died, 4 of whom were in remission. The median follow-up of the patients was 38 months. The 5-year overall survival and event-free survival were and 88.5% (95% CI: 77.1?94.4) and 78.7% (95% CI: 69.8?88.4), respectively. Our results are comparable to those in HICs in spite of the limited resources and the relatively low socioeconomic status of the Lebanese population. Children treated on this protocol experienced significant toxicity necessitating expert supportive care, but benefited from improved cure rates and prolonged survival. Am. J. Hematol. 87:678?683, 2012. ? 2012 Wiley Periodicals, Inc.
ER  - 
